| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Chief Financial Officer
6 companies
Coughlin Timothy is a Chief Financial Officer at NBIX, with reported holdings spanning 6 companies. Recent filings cover 2 purchases and 7 sales. Those positions are worth an estimated $9.1M at current prices.
Our model assigns Coughlin Timothy a strong insider score of 75/100, based on 3 past trades. Over a 12-month horizon, 100.0% of those trades were profitable, with an average 12-month return of +88.9%.
Coughlin Timothy's largest disclosed position is in NBIX as Chief Financial Officer, worth about $6.0M. The recent filings there lean toward selling, a net 4,213 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 12, 2026 | TVTX Travere Therapeutics, Inc. | Director | Sale+OE10b5-1 | 10,000 | $50.07 | $500,747.00 | -15.1% | +29.7% | - | |
| May 15, 2026 | TVTX Travere Therapeutics, Inc. | Director | Sell10b5-1 | 3,250 | $43.49 | $141,342.50 | -5.9% | +44.2% | - | |
| Oct 31, 2025 | TVTX Travere Therapeutics, Inc. | Director | Sale+OE10b5-1 | 18,000 | $35.03 | $630,601.20 | -24.5% | -9.0% | - | |
| May 30, 2024 | ATYR Atyr Pharma Inc | Director | Buy | 50,000 | $1.75 | $87,500.00 | +833.3% | +5.1% | +154.0% | |
| Jun 3, 2022 | FATE Fate Therapeutics Inc | Director | Sell | 1,439 | $22.81 | $32,823.59 | -2.4% | +14.3% | -77.8% | |
| Feb 6, 2017 | NBIX Neurocrine Biosciences Inc | Chief Financial Officer | Sell | 963 | $43.14 | $41,543.82 | -0.7% | - | - | |
| Feb 3, 2017 | NBIX Neurocrine Biosciences Inc | Chief Financial Officer | Sell | 1,500 | $42.55 | $63,825.00 | -1.1% | - | - | |
| Jan 17, 2017 | NBIX Neurocrine Biosciences Inc | Chief Financial Officer | Sell | 1,750 | $40.65 | $71,137.50 | -1.3% | - | - | |
| Nov 23, 2016 | FATE Fate Therapeutics Inc | Director | Buy | 56,390 | $2.66 | $149,997.40 | New | - | - |